Eli Lilly

News

traditional red and black painted bamboo walkway in Japan

Lilly gets second approval, in Japan, for Alzheimer's drug

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug.

News

Noom offers cut-price compounded GLP-1 drug for obesity

Digital health company Noom has launched a compound pharmacy-made version of Novo Nordisk's obesity drug semaglutide to make the drug more accessible to consumers in the US.

News

Lilly on alert as new Kisqali approval threatens Verzenio

Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly.

News

Lilly ramps up Irish manufacturing investment by $1bn

Eli Lilly has added $1 billion to its investment plan for a new manufacturing facility in Ireland that will be used to produce its Alzheimer's therapy donanemab.

News

Genetic Leap image of Genetic Intelligence

Lilly adds to genetic meds push with Genetic Leap alliance

In its second R&D alliance this week, Eli Lilly has formed a partnership with Genetic Leap, a startup that focuses on applying artificial intelligence to the discovery of RNA-targeted t

News

Samir Ounzain, CEO and co-founder of Haya Therapeutics

Lilly to hunt non-coding DNA for obesity drugs in $1bn deal

Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA.

Lilly gets second approval, in Japan, for Alzheimer's drug

Noom offers cut-price compounded GLP-1 drug for obesity

Lilly on alert as new Kisqali approval threatens Verzenio

Lilly ramps up Irish manufacturing investment by $1bn

Lilly adds to genetic meds push with Genetic Leap alliance

Lilly to hunt non-coding DNA for obesity drugs in $1bn deal

CEPI steps in to fund Moderna's pandemic flu jab

How to meet your physicians where they are online

Eli Lilly

Editor's Picks